NewAmsterdam Pharma amends CSO Kastelein's employment agreement with enhanced severance

NewAmsterdam Pharma Co N.V.

Amended agreement effective July 1, 2025; replaces November 2022 pact.
Termination without cause entitles Kastelein to 12 months base salary, earned bonus, and prorated annual bonus.
Change-in-control trigger: same severance plus acceleration of all time-based stock options and equity awards.
Exercise period for certain vested options extended upon qualifying termination.
Kastelein remains Chief Scientific Officer and a director; no departure announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.